RenovaCare products are under development and not approved for sale in the United States.

RenovaCare products are under development and not approved for sale in the United States.

RenovaCare Highlights Clinical Results From 44 Severe Burn Patients Published in Medical Journal

New York, Pittsburgh & Berlin – January 30, 2018 – RenovaCare, Inc., (OTCQB: RCAR), today highlighted an analysis of treatment results from 44 patients treated for severe second-degree wide-area burn injuries, as published in Burns, the peer-reviewed Journal of the International Society for Burn Injuries. The treatment method, which involved isolating and spraying the patient’s own skin stem cells on to burn wounds, is the technology underlying the RenovaCare patented SkinGun™* and CellMist™ System*.

RenovaCare Comments On Recent Market Activity

New York & Pittsburgh & Berlin – January 8th, 2018 – RenovaCare, Inc. (“RenovaCare” or the “Company”) (OTCQB: RCAR), developer of the SkinGun™ and CellMist™ System for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today announced that on January 3rd, 2018, OTC Markets Group Inc. (“OTC Markets”)…